The Wnt signalling pathway in beta-cells has been linked to the development of type 2 diabetes. Investigating the impact of a non-canonical Wnt ligand, Wnt4, on beta-cell function we found that in INS-1 cells, Wnt4 was able to completely block Wnt3a stimulated cell growth and insulin secretion. However, despite high levels of Wnt4 protein being detected in INS-1 cells, reducing the expression of Wnt4 had no impact on cell growth or Wnt3a signalling. As such, the role of the endogenously expressed Wnt4 in beta-cells is unclear, but the data showing that Wnt4 can act as a negative regulator of canonical Wnt signalling in beta-cells suggests that this pathway could be a potential target for modulating beta-cell function.
Wnt signalling was first proposed to be important in the pathogenesis of type 2 diabetes when variants in the transcription factor TCF7L2, a key component of the Wnt pathway, were discovered as strong risk factors for this illness [1] . Subsequent studies implicated β-cell dysfunction as the underlying cause of diabetes in patients with the TCF7L2 risk variant [2] [3] [4] [5] and have suggested that Wnt signalling plays an important role in both pancreatic development and in the function of mature pancreatic islets [6] . The activation of the canonical Wnt pathway, by ligands such as Wnt3a, has been of particular interest as it can increase β-cell proliferation, decrease apoptosis and improve glucose stimulated insulin secretion [6] [7] [8] [9] [10] [11] [12] . However there is now increasing evidence that non-canonical Wnt ligands such as Wnt4 can antagonise the signalling mediated by Wnt3a and may play an equally important role in β-cell function [13] [14] [15] .
The Wnt signalling pathway is mediated by Wnt ligands binding to cell surface receptors known as Frizzled (Fzd) molecules. Downstream signalling from these receptors appears to follow distinct pathways [16, 17] . The best characterised of these is the "canonical pathway" which regulates gene transcription by controlling the protein levels and cellular localisation of β-catenin [18] . In the nucleus β-catenin can act as a transcription factor (along with its cofactors TCF/LEF) to promote gene transcription of effectors of Wnt signalling, such as c-myc and cyclin D2. In contrast, the non-canonical pathways, such as those stimulated by Wnt4 are β-catenin independent and have been shown to antagonise the canonical Wnt pathway in several cell types [13, 14, [19] [20] [21] .
Our previously published data [22] showed that most Wnt ligands were either not expressed (including the canonical Wnt ligand, Wnt3a) or were present at only very low levels in a βcell line. The exception was Wnt4 which was expressed at levels more than 10 fold higher than any other Wnt ligand [22] . In addition Wnt4 protein has been detected in adult mouse islets but not in several other tissues including liver and kidney [14] . Wnt4 has also been found to be upregulated in the islets of two different insulin resistant mouse strains [14] and
in the islets of patients with type 2 diabetes [23] suggesting that Wnt4 may have islet specific functions in adults and a possible role in the development of diabetes.
In this paper we set out to determine the function of Wnt4 in pancreatic β-cells. Our data shows that the endogenous Wnt4 present in β-cells is not secreted and has no impact on βcell growth or β-catenin levels. In contrast treatment of β-cells with exogenous Wnt4 is able to antagonise canonical Wnt signalling leading to inhibition of Wnt3a stimulated β-cell proliferation and insulin secretion.
Material and Methods:

Immunohistochemistry
Paraffin embedded human pancreatic sections were obtained from two different healthy non diabetic cases (60 year old male (202/75) and 76 year old female (329/66)) from the Exeter Archival Diabetes Biobank. All samples were studied with ethical approval.
Immunohistochemisty was carried out as previously described [24] . Sections were incubated with primary Wnt4 antibody (AF745; RnD systems; 1/25) before incubation with flurochromeconjugated secondary antibody (Goat anti-rabbit Fluor488) for 1hr (room temperature).
Tissue sections were then incubated with insulin (A0564; Dako; 1/600) and glucagon (AB10988; Abcam; 1/2000) primary antibodies for 1hr followed by flurochrome-conjugated secondary antibody (Goat anti-guinea pig Fluor647 and Goat anti-mouse Fluor568 1/400) and DAPI (1/1000) for 1 hour. Immunofluorescence image collection and processing was achieved using a Leica DM4000 B LED upright fluorescence microscope and Leica Image analysis software (LAS AF).
Cell culture:
INS-1 cells were grown in RPMI 1640 medium containing 11mM glucose, supplemented with 10% (v/v) foetal bovine serum, 2mM L-glutamine, 100µg/ml penicillin, 100µg/ml streptomycin and 50mM β-mercaptoethanol.
To determine cell growth, cells were treated with test ligands in 1% (v/v) serum containing media and counted using a haemocytometer.
Wnt4 siRNA of INS-1 cells
INS-1 cells were transfected with 10nM silencer select siRNA Wnt4 s136596 (Lifetech) using lipofectamine RNAi MAX (Lifetech) diluted in optimem (Gibco) media. A scrambled siRNA was used as a negative control.
Wnt4 ELISA
INS-1 cells were cultured for 72hrs before lysis in PBS by repeated freeze thawing. The media from the cultured cells was concentrated approximately ten fold using an Amico Ultra-15 centrifugal device. Levels of Wnt4 were measured using a Cusabio Wnt4 rat ELISA according to the manufacturer's instructions.
Western blotting
Whole cell lysates from INS-1 cells were prepared as previously described [25] . Nuclear and cytoplasmic protein fractions were separated using a nuclear and cytoplasmic extraction kit EDTA with the addition of protease inhibitor and phosphatase inhibitors).
Protein lysates were used in western blotting (previously described [25] ) using the following primary antibodies and concentrations: Wnt4 (M70; Santa Cruz) 1 in 1000, Total β-catenin 
Statistical analysis
Data is presented as mean±SEM of treated samples compared to the untreated control.
Significant differences between treatment and control values were determined by ANOVA followed by a Mann-Whitney test and Kruskal-wallis test. P values <0.05 were considered significant.
Results:
Functional impact of Wnt4 on β-cell growth and insulin secretion
To investigate the functional impact of Wnt4 on beta-cells, INS-1 cells were treated with Wnt4 alone or in combination with Wnt3a and the impact on cell growth and insulin secretion measured. As expected, Wnt3a caused an increase in cell proliferation ( Fig 1A) and
increased insulin secretion stimulated by high glucose levels ( Fig 1B) . Wnt4 alone however had no impact on these parameters, but was able to completely block Wnt3a stimulated increases in cell growth and insulin secretion ( Fig 1A+B) , showing that Wnt4 is able to functionally inhibit the actions of Wnt3a.
Wnt4 mediated modulation of the canonical Wnt signalling pathway
We next sought to determine the mechanism by which Wnt4 can inhibit Wnt3a actions in βcells. Stimulation of canonical Wnt signalling is characterised by the stabilisation of β-catenin protein due to inhibition of phosphorylation on two key sites (Ser 37 and Thr 41 ) by GSK3β.
This hypo-phosphorylated form of β-catenin is referred to as 'active' β-catenin and is used as a marker of activation of the canonical pathway [6, 18] . In these experiments we have used two antibodies, one which recognises the hypo-phosphorylated form (referred to as 'active')
and another that will detect all β-catenin protein regardless of its phosphorylated state (referred to as 'total').
As expected, treatment of INS-1 cells with Wnt3a caused an increase in the levels of both total and active β-catenin protein in the cytoplasmic and nuclear cell protein fractions ( Fig   1C+D) . In contrast, treatment of INS-1 cells with Wnt4 didn't increase protein levels of active β-catenin, but surprisingly did increase protein levels of total β-catenin in both cytoplasmic and nuclear fractions ( Fig 1C+D) . When INS-1 cells were treated with a combination of Wnt3a and Wnt4, Wnt3a mediated increases in cytoplasmic and nuclear active β-catenin were prevented by Wnt4 ( Fig 1C+D) despite the continued presence of elevated total βcatenin protein levels ( Fig 1C+D) .
mRNA levels of β-catenin were also measured in INS-1 cells treated with Wnt3a and Wnt4.
No changes in β-catenin mRNA expression were detected with either ligand alone or in combination (Fig 2A) , suggesting that, as expected from the mechanism of the Wnt signalling pathway, any changes in protein levels of β-catenin caused by Wnt3a or Wnt4
were not due to changes in gene expression.
To test the idea that Wnt4 acts as a receptor antagonist of Wnt3a [14] , cells were treated with the specific GSK3β inhibitor, 1-AKP to activate the Wnt signalling pathway downstream
of the Wnt3a receptor. Wnt4 was able to inhibit the increase in active β-catenin protein stimulated by 1-AKP ( Fig 2B) , suggesting that inhibition of Wnt3a mediated signalling by Wnt4 is not due to antagonism at the receptor level.
Wnt4 has previously been shown to increase levels of β-catenin in the plasma membrane, suggesting that this might be a mechanism by which it could antagonise canonical Wnt signalling [21] . We investigated this theory and found that both Wnt3a and Wnt4 increased incorporation of β-catenin into the cell membranes, with no additive effect when both ligands were used in combination ( Fig 2C) .
To determine if Wnt4 prevents Wnt3a stimulated cell growth through inhibition of β-catenin mediated gene transcription, mRNA levels of cyclin D2, a key target gene of canonical Wnt signalling, was measured. As expected treatment of INS-1 cells with Wnt3a increased levels of cyclin D2 mRNA. Unexpectedly however treatment with Wnt4 alone had a similar effect and did not prevent the Wnt3a stimulated increases in cyclin D2 expression ( Fig 2D) .
Wnt4 expression and localisation:
Having shown that β-cells can respond to exogenous treatment with Wnt4 we sought to determine the potential source of this ligand using immunohistochemistry in human islet sections. In agreement with Lee et al [23] we found strong expression of Wnt4 in α-cells ( Fig   3) . However there was also staining for Wnt4 detectable at a lower intensity throughout the islet in insulin positive cells. These data suggest that in islets Wnt4 is expressed in both α and β-cells, with higher levels detected in α-cells.
To determine if the Wnt4 detected in the β-cells has a functional role we reduced levels of Wnt4 in INS-1 cells using Wnt4 specific siRNA ( Fig 4A) . This reduction of Wnt4 protein didn't cause any change in the basal rate of cell growth ( Fig 4B) . In addition β-cells with reduced Wnt4 expression didn't show any enhancement in Wnt3a mediated increases in active βcatenin levels when treated with Wnt ligands (Fig 4C) , suggesting that endogenous Wnt4 doesn't moderate the signalling activity stimulated by exogenous sources of Wnt3a.
To establish whether Wnt4 is secreted from β-cells we measured Wnt4 in the culture media of Wnt4 were detectable in the cell media, suggesting that Wnt4 is not secreted by INS-1 cells ( Fig 4D) .
Discussion:
There is considerable interest in the action of Wnt signalling in modulating β-cell growth and function, with the implication that changes in this pathway may be causative in the on-set of β-cell dysfunction that occurs in type 2 diabetes. In this paper we present unique functional data showing that Wnt4 is able to inhibit Wnt3a stimulated increases in β-cell growth and glucose stimulated insulin secretion.
Interestingly previous studies have suggested that canonical Wnt signalling is not active in mature islets [14, 23] . It seems plausible that the lack of activity may be due to high levels of reported here and by others [23] points to an intra islet source of Wnt4. However a recent paper suggests that Wnt ligands secreted by adipose and muscle tissue can impact β-cell function [15] .
Previous reports have proposed various mechanisms by which Wnt4 may antagonise the canonical Wnt signalling pathway. One of these is that Wnt4 may act as a receptor antagonist to Wnt3a preventing Wnt3a activation of target cell surface receptors [14] . The results presented here show that Wnt4 is able to inhibit increases in active β-catenin levels mediated by the specific GSK3β inhibitor 1-AKP. This would suggest that Wnt4 is able to inhibit the canonical Wnt pathway at or downstream of GSK3β, rather than acting as a receptor antagonist. Another possibility is that Wnt4 can increase β-catenin incorporation in adhesion junctions in the cell membrane [21] thus inhibiting canonical Wnt signalling by reducing the pool of β-catenin available for mediating gene transcription. We find that both Wnt3a and Wnt4 increase levels of β-catenin protein in the membrane fraction in INS-1 cells, with no further increase when cells are treated with both ligands together. This suggests increased incorporation of β-catenin at the adhesion junctions is not the mechanism by which Wnt4 inhibits Wnt3a mediated signalling.
As expected from an inhibitor of the canonical Wnt signalling pathway we find that Wnt4 is able to inhibit the Wnt3a mediated increase in the hypo-phosphorylated ('active') form of β- phosphorylated β-catenin is rapidly degraded in the proteasome ensuring that cytoplasmic βcatenin proteins levels remain low [27] . Wnt4 treatment did not increase the expression of the β-catenin mRNA suggesting that increased β-catenin protein levels are due to reduced proteasomal degradation rather than increased gene transcription. As Wnt4 did not increase levels of 'active' β-catenin, the increased β-catenin seen with Wnt4 is presumably still phosphorylated by GSK3β, suggest that Wnt4 may disrupt the ubiquitin proteasome pathway or stabilise β-catenin by phosphorylating the protein on a different residue. This GSK3β independent stabilisation of β-catenin has recently been described in tumour cells in response to unsaturated fatty acids in [28] .
In the nucleus β-catenin acts, in combination with tcf/lef, as a transcription factor leading to increased transcription of β-catenin sensitive genes, such as cyclin D2. Interestingly we found that Wnt4, despite leading to decreases in active β-catenin in the nucleus, wasn't able to prevent Wnt3a activation of cyclin D2. More surprisingly, Wnt4 itself was able to increase expression of cyclin D2 in β-cells, presumably due to its ability to increase levels of total βcatenin in the nucleus. These observations imply that in addition to Wnt4 preventing increases in active β-catenin levels, it may also be able to act downstream of β-catenin mediated gene transcription to prevent Wnt3a mediated cell growth and insulin secretion.
In conclusion the present results provide strong evidence that Wnt4 is able to functionally inhibit the actions of canonical Wnt signalling in pancreatic β-cells, leading to the inhibition of Wnt3a mediated increases in cell growth and insulin secretion. As such given the strong link of canonical Wnt signalling with diabetes on-set we suggest that modulation of Wnt4 protein expression in islets or targeting Wnt4 signalling pathways may represent a potential new target for the treatment of diabetes.
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